1. Devore R, Blanke C, Denham C, Hainsworth JD, Gralla RJ, Koletsky AJ, Savaraj N, Vogal CL, Sarma GP, Brooks DJ, Petit RG, Elfing GL, Schaaf LJ, Hanover CK, Miller LL (1998) Phase II study of CPT-11 in patients with previously treated small cell lung cancer. Proc Amer Soc Clin Oncol 17: 451a
2. Elias AD, Ayash L, Frei E, Skarim AT, Hunt M, Wheeler C, Schwartz G, Mazanet R, Tepler I, Eder JP (1993) Intensive combined modality therapy for limited-disease small cell lung cancer. J Natl Cancer Inst 85: 559–566
3. Evans WK, Feld R, Murray N, William A, Coy P, Osoba D, Shepherd FA, Clark DA, Levitt M, McDonald A, Wilson K, Shelley W, Pater J (1987) Superiority of alterrating cross resistant chemotherapy in extensive small cell lung cancer. A multicenter randomized clinical trial by National Cancer Institute of Canada. Ann Intern Med 107: 451–458
4. Fukuda M, Nishio K, Kanzawa F, Ogasawara H, Ishida T, Arioka H, Bojanwski M, Oka M, Saijo N (1996) Synergism between cisplatin and topoisomerase I inhibitors, NB506 and SN38, in human small cell lung cancer cells. Cancer Res 56: 789–793
5. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M, Suemasu K (1991) Randomized trial of cyclophosplamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer. J Natl Cancer Inst 83: 855–861